GlassScriptPhysician profile
Tara K Robbins
NPI 1972769438
$3,382.55
in general payments reported to CMS, 2019-2025
29 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $1,237 · 2021: $481 · 2022: $211 · 2023: $147 · 2024: $254 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $454.66 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $390.33 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $341.65 | 2019-2025 | Breztri |
| Amgen INC. | $223.15 | 2019-2023 | Prolia, Evenity |
| Abbvie INC. | $212.89 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $177.61 | 2020-2025 | Gardasil 9, Capvaxive, Varivax |
| Allergan, INC. | $170.09 | 2020 | |
| Pfizer INC. | $164.57 | 2019-2025 | |
| Amarin Pharma, INC. | $159.42 | 2019-2021 | |
| Organon LLC | $156.95 | 2022 | |
| Alnylam Pharmaceuticals INC. | $146.21 | 2025 | Amvuttra |
| Glaxosmithkline, LLC. | $121.73 | 2021-2025 | Shingrix, Bexsero, Arexvy |
| Exact Sciences Corporation | $110.02 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $86.84 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $56.29 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.91 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.73 | 2020-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $42.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $41.34 | 2021-2024 | |
| Viiv Healthcare Company | $37.30 | 2025 | Apretude |
| Antares Pharma, INC. | $35.11 | 2021 | |
| Elite Orthopedics, LLC | $33.81 | 2020 | |
| Mylan Specialty L.P. | $28.43 | 2020 | |
| Zyla Life Sciences, INC. | $22.30 | 2019-2020 | |
| Phadia US INC. | $15.75 | 2021 | |
| Gilead Sciences, INC. | $12.77 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.00 | 2020 | |
| Astellas Pharma US INC | $11.05 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.